BridgeMD
New treatment option for Post-Traumatic Stress Disorder
Official title Disrupting Fear-based Memory Consolidation
ClinicalTrials.gov ID: NCT05560113
What this study is testing
- What it's testing
- This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-traumatic stress disorder (PTSD). If successful, the study results would anchor a potential advance in the treatment of patients after a traumatic event and seed future animal and clinical studies of emotional sensory cortical memory consolidation to reduce the prevalence and negative sequelae of PTSD.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Ability to provide informed consent
- Willingness to participate in study
- No history of musculoskeletal impairment or neurological disease
- Clinical diagnosis of PTSD for individuals in the PTSD group.
You likely can't join if
- Any participant outside the age range
- Participants that show signs of dementia (score \< 20 on the Montreal Cognitive Assessment)
- Participants that have a history of major head trauma, a neurodegenerative disorder, or recent (\<6 months) substance abuse;
- Participants that had a recent history of Central Nervous System (CNS) active drugs that may influence cortical excitability or learning; or
- Participants that report contraindications to TMS or MRI - if participating in the TMS/MRI experiments
- Current psychoactive medication usage
See the full eligibility criteria
- Ability to provide informed consent
- Willingness to participate in study
- No history of musculoskeletal impairment or neurological disease
- Clinical diagnosis of PTSD for individuals in the PTSD group.
- Any participant outside the age range
- Participants that show signs of dementia (score \< 20 on the Montreal Cognitive Assessment)
- Participants that have a history of major head trauma, a neurodegenerative disorder, or recent (\<6 months) substance abuse;
- Participants that had a recent history of Central Nervous System (CNS) active drugs that may influence cortical excitability or learning; or
- Participants that report contraindications to TMS or MRI - if participating in the TMS/MRI experiments
- Current psychoactive medication usage
- Current symptoms of psychosis or bipolar disorder (as indicated by study staff through a clinical interview as part of that study).
- The study will exclude adults unable to consent, individuals who are not yet adults, pregnant women and prisoners on scientific grounds and to minimize risk.
The study team makes the final eligibility decision.
Where it's taking place
- Atlanta, Georgia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Atlanta, Georgia, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.